Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- ICT Academy mulls host of AVGC initiatives to tap into T.N. students’ potential in gaming sector
- Social media addiction, sedentary habits eating into health, productivity potential: Economic Survey
- India’s Green Commute Slows Down as EV Cabs Lose Spark
- Incentives for R&D: New foreign trade policy to retain key schemes despite WTO trouble